Bausch Health (BHC)
(Delayed Data from NYSE)
$9.38 USD
+0.18 (1.96%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $9.40 +0.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.38 USD
+0.18 (1.96%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $9.40 +0.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
Implied Volatility Surging for Bausch (BHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bausch (BHC) stock based on the movements in the options market lately.
New Strong Sell Stocks for May 19th
by Zacks Equity Research
ASX, CNMD, and BHC have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2022.
Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
by Kanishka Das
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed the most recent trading day at $18.85, moving -0.84% from the previous trading session.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
by Indrajit Bandyopadhyay
The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.
Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $21.48 in the latest trading session, marking a -0.88% move from the prior day.
Aerie (AERI) Expands Market Presence Despite Stiff Competition
by Zacks Equity Research
Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States.
Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Bausch Health (BHC) closed at $23.23, marking a -1.69% move from the previous day.
Bausch Health (BHC) Stock Moves -0.56%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bausch Health (BHC) closed at $23.17, marking a -0.56% move from the previous day.
Bausch (BHC) Up 1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed the most recent trading day at $24.05, moving +1.69% from the previous trading session.
Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bausch Health (BHC) closed at $21.97, marking a -1.08% move from the previous day.
Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $22.56 in the latest trading session, marking a -0.84% move from the prior day.
Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.
Bausch Health (BHC) Beats Q4 Earnings Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 17.59% and 0.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.
Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $24.74 in the latest trading session, marking a -1.55% move from the prior day.
Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $24.78 in the latest trading session, marking a +1.6% move from the prior day.
Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $24.39 in the latest trading session, marking a -0.53% move from the prior day.
Bausch Health (BHC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bausch Health (BHC) closed at $24.57, marking a +1.78% move from the previous day.
Should Value Investors Pick Bausch Health (BHC) Stock Now?
by Zacks Equity Research
Let's see if Bausch Health Companies Inc. (BHC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Anthem's (ANTM) Q4 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) Q4 results reflect better revenues and a solid contribution from its Government Business and IngenioRx businesses, partly offset by escalating expenses.